Inolitazone (dihydrochloride), CAS 223132-38-5

Product Description: Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.

Applications: Cancer-Kinase/protease

Formula: C27H28Cl2N4O4S

Citations: Cancer Med. 2018 May;7(5):1955-1966. /Int J Oncol. 2018 Jun;52(6):1991-2000. /Exp Cell Res. 2017 Dec 15;361(2):246-256. /Front Microbiol. 2019 Jan 8;9:3257.

References: [1]Copland JA, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13;25(16):2304-17./[2]Marlow LA, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009 Feb 15;69(4):1536-44.

CAS Number: 223132-38-5

Molecular Weight: 575.51

Compound Purity: 98.86

Research Area: Cancer

Solubility: DMSO : 2 mg/mL (ultrasonic;warming;heat to 80°C)/H2O : < 0.1 mg/mL

Target: PPAR

• SKU: MEXHY-14792B-25
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-14792B-25
• Package Unit: 25 mg
• Quantity Unit: STK